BTIG Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Maintains Target Price $48

Futu NewsMay 14 20:34 · Ratings

Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target

TipRanksMay 14 20:15 · Ratings

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

GlobeNewswireMay 13 10:15

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

GlobeNewswireMay 12 20:00

As the ASCO annual meeting approaches, the number of LBA for domestically innovative drugs has reached a new high, with three key investment themes worth noting.

A total of 63 studies were selected as Late-Breaking Abstracts (LBA) at this year's ASCO, including 13 studies from 12 companies based in China; notable domestically developed innovative drugs selected for LBA include AK112 from Akeso Biopharma and sintilimab plus chemotherapy from Innovent Bio; Huatai Securities stated that China's innovative drug sector is rapidly emerging as a defining force in global oncology treatment paradigms, with first-line lung cancer being one of the key focuses at this year’s ASCO.

cls.cnMay 4 14:15

Ascentage Pharma Adds Executive Equity Grants to AGM Agenda and Updates Proxy Process

TipRanksApr 30 22:42